BioInvent International AB (STO:BINV) announced on Tuesday the signing of a manufacturing agreement with an undisclosed US cell therapy company for the production of cGMP compliant material to support their clinical development programmes.
This manufacturing agreement is expected to generate revenues of approximately USD1.5m, mainly in 2019.
BioInvent International is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government